VivoSeq
Oncology

Mature B-Cell Malignancies

4

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Mature B-cell Malignancies is an early-stage landscape with 4 programs across 5 companies. The most active players are BeOne Medicines, BeiGene, Roche.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

2 programs

Phase 1BeiGene logo

BeiGene

1 program

Phase 1Roche logo

Roche

1 program

Phase 1B

Beijing InnoCare Pharma Tech Co., Ltd.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 14

Sonrotoclax

BeOne Medicines

Zanubrutinib

BeOne Medicines

Obinutuzumab

Roche

BGB-11417

BeiGene

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

5

clinical trials

Active, not recruiting3 · 60%
Recruiting2 · 40%

Clinical Trials

Trial Activity

The Study of ICP-248 in Patients With Mature B-cell Malignancies
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1·NCT05728658·191 enrolled
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Active, not recruiting·BBeOne Medicines·Phase 1·NCT05828589·112 enrolled
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT06564038·276 enrolled
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies
Active, not recruiting·BeiGene logoBeiGene·Phase 1·NCT04883957·64 enrolled
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Active, not recruiting·BeiGene logoBeiGene·Phase 1·NCT04277637·437 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)